17:02 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput, CRISPR interference (CRISPRi)-based method of mapping genetic interactions could help identify new drug targets for cancer and genetic disorders. The method involves: selecting sgRNAs against genes identified...
17:19 , Aug 3, 2018 |  BC Week In Review  |  Financial News

CRISPR diagnostics play Mammoth raises $23M series A

Mammoth Biosciences (San Francisco, Calif.) raised $23 million on July 31 in a series A round led by Mayfield Partners, with participation from fellow seed investors NFX and 8VC. Co-founder and CEO Trevor Martin told BioCentury...
22:57 , Jul 19, 2018 |  BC Extra  |  Preclinical News

Inhibiting EIF2AK1 could help treat sickle cell disease

Researchers from Children’s Hospital of Philadelphia and University of Pennsylvania showed that inhibiting EIF2AK1 to increase fetal hemoglobin could help treat sickle cell disease. As genetic diseases such as SCD and some thalassemias affect patients only...
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A non-viral CRISPR-Cas9-based method for engineering patient-derived T cells could be used to generate personalized cell therapies for cancer and autoimmune diseases. The method consists of co-electroporating T cells collected from the...
16:04 , Jul 16, 2018 |  BC Extra  |  Preclinical News

On-target mutations latest worry for CRISPR stocks

On the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s group from the Wellcome Sanger Institute shifted the spotlight to on-target mutations that could result from the technology....
20:51 , Jul 12, 2018 |  BC Extra  |  Preclinical News

Virus-free CRISPR T cell editing

A team led by University of California San Francisco researchers developed a non-viral method to engineer T cell genomes in about one week using CRISPR/Cas9 DNA editing. The method could reduce the time and cost...
21:45 , Jul 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Gold-based nanoparticles could be used to deliver CRISPR-Cas9 and CRISPR-Cas12a constructs for neurological diseases. The nanoparticles are generated by conjugating gold nanoparticles to DNA oligonucleotides that bind to the CRISPR endonuclease and single-guide...
23:00 , Jun 25, 2018 |  BC Extra  |  Preclinical News

Brain-targeted CRISPR could treat autism behaviors

Researchers at University of Texas Health Science Center, University of California Berkeley and GenEdit Inc. (Berkeley, Calif.) used gold nanoparticles as a non-viral method to deliver the CRISPR gene editing complex into the brain and...
22:55 , Jun 22, 2018 |  BC Extra  |  Preclinical News

Blocking LSD1 could activate cancer immune response via HERV

A Harvard Medical School team led by immunology and pathology professor Arlene Sharpe has shown inhibiting lysine-specific demethylase (LSD1; KDM1A) increases human endogenous retrovirus (HERV) transcription to activate an immune response that could help treat...
18:09 , Jun 22, 2018 |  BC Week In Review  |  Company News

UC Regents get CRISPR guide RNA patent in U.S.

The U.S. Patent Office on June 19 granted a patent related to CRISPR-Cas9 gene editing technology to the Regents of the University of California, the University of Vienna and Emmanuelle Charpentier covering use of guide...